EVANGELIA BOUNOUVI

Dr. EVANGELIA BOUNOUVI


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2021 in Genes
Verified
Journal Article
Open access
PDF file
APAnna Papadopoulou
Anna Papadopoulou
EBEVANGELIA BOUNOUVI
EVANGELIA BOUNOUVI
FKFotini-Heleni Karachaliou
Fotini-Heleni Karachaliou
Calcium (Ca) and Phosphorus (P) hold a leading part in many skeletal and extra-skeletal biological processes. Their tight normal range in serum mirrors their critical role in human well-being. The signalling “voyage” starts at Calcium Sensing Receptor (CaSR) localized on the surface of the parathyroid glands, which captures the “oscillations” of extracellular ionized Ca and transfers the signal downstream. Parathyroid hormone (PTH), Vitamin D, Fibroblast Growth Factor (FGF23) and other receptors or ion-transporters, work synergistically and establish a highly regulated signalling circuit between the bone, kidneys, and intestine to ensure the maintenance of Ca and P homeostasis. Any deviation from this well-orchestrated scheme may result in mild or severe pathologies expressed by biochemical and/or clinical features. Inherited disorders of Ca and P metabolism are rare. However, delayed diagnosis or misdiagnosis may cost patient’s quality of life or even life expectancy. Unravelling the thread of the molecular pathways involving Ca and P signaling, we can better understand the link between genetic alterations and biochemical and/or clinical phenotypes and help in diagnosis and early therapeutic intervention.

4 May 2017 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
EBEVANGELIA BOUNOUVI
EVANGELIA BOUNOUVI
APAnna Papadopoulou
Anna Papadopoulou
MVMarie T. Vanier
Marie T. Vanier
GNGeorgia Nyktari
Georgia Nyktari
SKSpyridon Kanellakis
Spyridon Kanellakis
ADArgyrios Dinopoulos
Argyrios Dinopoulos
Niemann-Pick type C disease (NPC) is an autosomal recessive, neurovisceral, lysosomal storage disorder with protean and progressive clinical manifestations, resulting from mutations in either of the two genes, NPC1 (~95% of families) and NPC2. Contrary to other populations, published evidence regarding NPC disease in Greece is sparse. The study population consisted of two Greek NPC patients and their extended pedigree. Patients’ clinical, biochemical, molecular profiles and the possible correlations are presented. Genotyping was performed by direct sequencing. Mutations’ origin was investigated through selected exonic NPC1 polymorphisms encountered more frequently in a group of 37 Greek patients with clinical suspicion of NPC disease and in a group of 90 healthy Greek individuals, by the use of Haplore software. Two novel NPC1 mutations, [IVS23 + 3insT (c.3591 + 3insT) and p. K1057R (c.3170A > C)] were identified and each mutation was associated with a specific haplotype. One of the patients was entered to early treatment with miglustat and has presented no overt neurological impairment after 11.5 years. The splicing mutation IVS23 + 3insT was associated in homozygocity with a severe biochemical and clinical phenotype. A possible founder effect for this mutation was demonstrated in the Greek Island, as well as a different origin for each novel mutation. Longitudinal follow-up may contribute to clarify the possible effect of early miglustat therapy on the patient compound heterozygous for the two novel mutations.

29 July 2022 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
GPGeorge Papadopoulos
George Papadopoulos
APAnna Papadopoulou
Anna Papadopoulou
KKKonstantina Kosma
Konstantina Kosma
APAnastasios Papadimitriou
Anastasios Papadimitriou
VPVassiliki Papaevangelou
Vassiliki Papaevangelou
SKSophia Kitsiou-Tzeli
Sophia Kitsiou-Tzeli